Veracyte to Present Data on Diagnostic Tests for IPF and Lung Cancer at ATS 2016
Veracyte, Inc., recently announced that data from multiple studies supporting the ability of its diagnostic tests to help detect pulmonary disease, including idiopathic pulmonary fibrosis (IPF), will be presented at the American Thoracic Society (ATS) 2016 International Conference taking place in San Francisco. Veracyte will discuss findings from a total of eight studies, two as podium presentations.
The Percepta Bronchial Genomic Classifier, which is used to improve nonsurgical diagnosis of lung cancer, will be the subject of four of the company’s presentations. The data demonstrate the product’s clinical utility, cost-effectiveness, and analytical verification, the company said in a press release.
Four other presentations will focus on studies of the company’s in-development classifier to help distinguish IPF from other interstitial lung diseases. The findings will focus on IPF diagnostic difficulties, and the potential of Veracyte’s new product to overcome such challenges, enabling physicians to make better informed and accurate treatment decisions at an earlier disease stage. By improving the accuracy of diagnostic tests, the products could result in significant healthcare cost savings, and reduce the need for invasive diagnostic surgeries.
IPF, a type of interstitial lung disease affecting the tissue that supports the alveoli in the lungs, is characterized by the inflammation or accumulation of scar tissue (denominated fibrosis), leading to progressive loss of elasticity, failure of proper lung activity, and insufficient oxygenation of the bloodstream and organs. Importantly, IPF patients are at an increased risk for pulmonary hypertension, so early disease detection is of importance for risk-stratification, and listing for treatments such as lung transplantation.
“The data being presented at this year’s ATS conference further expand the substantial library of evidence demonstrating the ability of our Percepta classifier to help reduce unnecessary invasive procedures in lung cancer diagnosis,” said Bonnie Anderson, president and chief executive officer of Veracyte. “Additionally, we are excited to showcase multiple posters confirming the potential of our ILD classifier to help clinicians deliver more accurate and timely IPF diagnosis, without the need for surgery.”
A detailed list of Veracyte presentations at the ATS conference, running May 13–18, is available through this link.